by 
Cytotoxic drugs, also known as antineoplastic or chemotherapy drugs, are used to treat cancers and certain other neoplastic diseases. These drugs work by slowing or stopping the growth of fast-growing cells such as cancer cells. The global cytotoxic drugs contract manufacturing market has been witnessing significant growth driven by the rising prevalence of cancer across the world. According to the National Cancer Institute, cancer prevalence is expected to rise to 26 million by 2030 from an estimated 19.3 million in 2020. The growing healthcare expenditure to manage the rising cancer burden has led to increased adoption of outsourcing cytotoxic drug manufacturing to specialized contract development and manufacturing organizations (CDMOs).
Cytotoxic drugs produced through contract manufacturing are preferred by pharmaceutical companies due to advantages such as access to high quality manufacturing facilities, technical expertise, and reduced capital investment. With contract manufacturing services, drug manufacturers can focus on drug development while outsourcing the capital-intensive and complex manufacturing operations to CDMOs. This enables smaller pharmaceutical companies and those with limited manufacturing capabilities to cater to the demand for chemotherapy drugs.
The global cytotoxic drugs contract manufacturing market is estimated to be valued at US$ 6,285.2 Mn in 2023 and is expected to exhibit a CAGR of 9.1% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
One of the major trends in the cytotoxic drugs contract manufacturing market is the shift towards continuous manufacturing. Traditionally, cytotoxic drug manufacturing was carried out through batch manufacturing which involved multiple steps from synthesis to packaging. However, continuous manufacturing allows for a more integrated, efficient and flexible production process. Leading CDMOs are now adopting continuous manufacturing techniques such as continuous mixing and crystallization to improve process yields, reduce manufacturing costs and minimize environmental footprint. Another key trend is the growing outsourcing of cell and gene therapy manufacturing. With the rapid clinical development of advanced cell and gene therapies for cancer, CDMOs offering specialized services for viral vector production and cell processing are witnessing increasing demand. This is expected to drive the need for modernized cGMP manufacturing facilities with capabilities to handle complex biologics and novel modalities.
Porter’s Analysis
Threat of new entrants: The cytotoxic drugs contract manufacturing market requires high capital investment and regulatory approvals which pose significant barriers for new entrants.
Bargaining power of buyers: The presence of many contract manufacturing organizations gives buyers bargaining power in terms of price and quality.
Bargaining power of suppliers: Suppliers have moderate bargaining power due to the niche nature of APIs and complexity involved in cytotoxic drug manufacturing.
Threat of new substitutes: There are limited substitutes for cytotoxic drugs used in cancer treatment.
Competitive rivalry: The market is highly competitive with presence of large and small players globally.
Key Takeaways
The global cytotoxic drugs contract manufacturing market is expected to witness high growth over the forecast period. The global cytotoxic drugs contract manufacturing market is estimated to be valued at US$ 6,285.2 Mn in 2023 and is expected to exhibit a CAGR of 9.1% over the forecast period 2023 to 2030.
Regional analysis: North America is expected to hold the largest share in the global cytotoxic drugs contract manufacturing market during the forecast period. Factors such as strong presence of large biopharmaceutical companies, focus on outsourcing of manufacturing activities are driving the market growth in this region.
Key players: Key players operating in the cytotoxic drugs contract manufacturing market are Lonza Group, Piramal Group, Evonik Industries AG, Novasep Holding SAS, Merck KGaA (SAFC Pharma), Baxter Biopharma Solutions, AbbVie Contract Manufacturing, Cambrex Corporation, BSP Pharmaceuticals S.p.A., CordenPharma Internatisonal, Catalent, Inc., Albany Molecular Research Inc., Evotec, WuXi AppTec Co., Ltd., Pierre Fabre Laboratories, and Dishman Group.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
